Dermata Therapeutics, Inc. Common Stock (DRMA) Stock Price
DRMAStock
$1.34−74.95%52W
Market Cap$6.64M
P/E—
PEG Ratio—
Div yield—
Beta0.70
DRMA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-1.19%
Price vs S&P 500 (4W)23.11%
VGM Score33.38
DRMA Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.55 | -$0.74 | -34.55%(-$0.19) | |
| Q1 2026 | -$0.53 | -$0.48 | +9.43%(+$0.05) | |
| Q4 2025 | -$1.54 | -$1.52 | +1.30%(+$0.02) | |
| Q3 2025 | -$1.59 | -$1.65 | -3.77%(-$0.06) | |
| Q2 2025 | -$2.90 | -$1.66 | +42.76%(+$1.24) |
DRMA Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
DRMADermata Therapeutics, Inc. Common Stock | — | — | D | $1.34 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Dermata Therapeutics, Inc. Common Stock
Dermata Therapeutics develops OTC dermatology treatments for acne, psoriasis, rosacea, and seborrheic dermatitis. The company is advancing a once-weekly acne treatment leveraging its proprietary Spongilla technology platform for enhanced delivery and patient compliance. Dermata plans to expand Spongilla's application across dermatologic and aesthetic markets, including intradermal delivery of botulinum toxin, providing multiple revenue opportunities.